SC-51089

SC-51089 is a **synthetic, small molecule antagonist** selectively targeting the **prostaglandin E2 (PGE2) EP1 receptor**[6][7][8][9]. It has been widely used as a research tool to elucidate the role of EP1 receptors in neuroprotection, ischemic injury, and inflammatory processes, showing **central activity and neuroprotective effects in animal stroke models**[3]. SC-51089 exhibits selectivity, with potent antagonism at EP1 (Ki ≈ 1.3 µM), and much weaker activity at other prostanoid receptors (EP2, EP3, EP4)[7][8]. It is not an approved therapeutic; research is limited to **preclinical in vitro and in vivo models** for conditions such as cerebral ischemia and neurodegeneration[3][5][7]. SC-51089 has also demonstrated the ability to attenuate neurotoxicity and cell death induced by amyloid-β in neuroblastoma cells[5].

Brand names

SC-51089SC51089SC 51089

Other names

SC-51089SC51089SC 510898-chloro-dibenz[b,f][1,4]oxazepine-10(11H)-carboxylic acid 2-[1-oxo-3-(4-pyridinyl)propyl]hydrazide3-chloro-N'-(3-pyridin-4-ylpropanoyl)-6H-benzo[b][1,5]benzoxazepine-5-carbohydrazide